About sitagliptinantidiabetic agent, oral hypoglycaemicmechanism of action of sitagliptinvildagliptin is a dipeptidylpeptidase-4 (dpp-4) inhibitor that improves glycaemic control by preventing dpp-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thus prolonging incretin activity in response to ingestion of nutrients. this increases insulin sensitivity, decreases glucagon secretion and improves ?-cell function.indications for sitagliptintype 2 diabetes mellitusinteractions for sitagliptindigoxin: increase concentration of digoxin increased risk of hypoglycaemia when used with other anti-diabetic agents